Drug Search Results
More Filters [+]

Dihydrocodeine

Alternative Names: dihydrocodeine, trezix, dhc plus, synalgos-dc, synalgos-dc-a
Latest Update: 2014-12-31
Latest Update Note: Clinical Trial Update

Product Description

Dihydrocodeine is a synthetic opioid analgesic developed in the early 1900s. Its structure and pharmacokinetics are similar to that of codeine and it is used for the treatment of postoperative pain or as an antitussive. It is becoming increasingly important to assess the relative efficacy and harm caused by different treatments.  (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176625/)

Mechanisms of Action: OPR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Bulgaria | Colombia | Cyprus | Czech | Estonia | France | Germany | Hong Kong | Hungary | Ireland | Korea | Latvia | Malaysia | Malta | New Zealand | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Switzerland | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dihydrocodeine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title